JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

Search

Elanco Animal Health Inc

Closed

SectorHealthcare

17.08 3.14

Overview

Share price change

24h

Current

Min

16.89

Max

17.26

Key metrics

By Trading Economics

Income

75M

67M

Sales

173M

1.2B

P/E

Sector Avg

18.76

34.393

Profit margin

5.616

Employees

9,000

EBITDA

86M

261M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+5.64% upside

Dividends

By Dow Jones

Next Earnings

6 lis 2025

Market Stats

By TradingEconomics

Market Cap

2.2B

7B

Previous open

13.94

Previous close

17.08

News Sentiment

By Acuity

50%

50%

162 / 374 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

Elanco Animal Health Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

5 maj 2025, 11:29 UTC

Acquisitions, Mergers, Takeovers

Elanco Sells Non-Core Asset to Blackstone for $295 Million

5 maj 2025, 11:14 UTC

Acquisitions, Mergers, Takeovers

Elanco Sells Non-Core Asset to Blackstone for $295 Mln

5 maj 2025, 10:50 UTC

Acquisitions, Mergers, Takeovers

Elanco Animal Health: Monetization of This Non-Core Asset Will Be Used to Accelerate Debt Reduction >ELAN

5 maj 2025, 10:49 UTC

Acquisitions, Mergers, Takeovers

Elanco Sells Royalty and Milestone Rights for Lotilaner in Human Health to Blackstone for $295M

Peer Comparison

Price change

Elanco Animal Health Inc Forecast

Price Target

By TipRanks

5.64% upside

12 Months Forecast

Average 17.61 USD  5.64%

High 21 USD

Low 15 USD

Based on 11 Wall Street analysts offering 12 month price targets forElanco Animal Health Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

11 ratings

8

Buy

3

Hold

0

Sell

Technical Score

By Trading Central

9.77 / N/ASupport & Resistance

Short Term

Bullish Evidence

Intermediate Term

Strong Bullish Evidence

Long Term

Weak Bullish Evidence

Sentiment

By Acuity

162 / 374 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Elanco Animal Health Inc

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.